Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis: A reanalysis of 2 meta-analyses

Corinne G. Brooks, Wade N. Harrison, Shawn Ralston

Research output: Contribution to journalArticle

Abstract

IMPORTANCE: Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS) in acute viral bronchiolitis have suggested benefit. Neither study fully addressed the issue of excessive heterogeneity in the cohort of studies, indicating that it may be inappropriate to combine such dissimilar studies to estimate a common treatment effect. OBJECTIVE: To reanalyze the existing data set for sources of heterogeneity to delineate the population most likely to benefit from HS. DATA SOURCES: We used the previously analyzed cohort of randomized trials from 2 published meta-analyses comparing HS with normal saline (or, in 1 case, with standard of care) in infants hospitalized for bronchiolitis. We also repeated the search strategy used by the most recent Cochrane Review in the Medline database through September 2015. STUDY SELECTION: Eighteen randomized clinical trials of HS in infants with bronchiolitis reporting LOS as an outcome measure were included. DATA EXTRACTION AND SYNTHESIS: The guidelines used for abstracting data included LOS, study year, setting, sample size, type of control, admission/discharge criteria, adjunct medications, treatment frequency, mean day of illness at study enrollment, mean severity of illness scores, and mean age. MAIN OUTCOMES AND MEASURES: Weighted mean difference in LOS and study heterogeneity as measured by the l2 statistic. RESULTS: There were 18 studies included of 2063 infants (63% male), with a mean age of 4.2 months. The mean LOS was 3.6 days. Two main sources of heterogeneity were identified. First, the effect of HS on LOS was entirely sensitive to the removal of one study population, noted to have a widely divergent definition of the primary outcome. Second, there was a baseline imbalance in mean day of illness at presentation between treatment groups. Controllingfor either of these factors resolved the heterogeneity (l2 = reduced from 78% to 45% and 0%, respectively) and produced summary estimates in support of the null hypothesis (that HS does not affect LOS). There was a weighted mean difference in LOS of -0.21 days (95% CI, -0.43 to +0.02) for the sensitivity analysis and +0.02 days (95% CI, -0.14 to +0.17) for studies without unbalanced treatment groups on presentation. CONCLUSIONS AND RELEVANCE: Prior analyses were driven by an outlier population and unbalanced treatment groups in positive trials. Once heterogeneity was accounted for, the data did not support the use of HS to decrease LOS in infants hospitalized with bronchiolitis.

Original languageEnglish (US)
Pages (from-to)577-584
Number of pages8
JournalJAMA pediatrics
Volume170
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Viral Bronchiolitis
Meta-Analysis
Length of Stay
Bronchiolitis
Sick Leave
Population
Therapeutics
Information Storage and Retrieval
Standard of Care
Sample Size

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis : A reanalysis of 2 meta-analyses. / Brooks, Corinne G.; Harrison, Wade N.; Ralston, Shawn.

In: JAMA pediatrics, Vol. 170, No. 6, 01.06.2016, p. 577-584.

Research output: Contribution to journalArticle

@article{bdb679a9b53f4450b58b29306774cd59,
title = "Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis: A reanalysis of 2 meta-analyses",
abstract = "IMPORTANCE: Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS) in acute viral bronchiolitis have suggested benefit. Neither study fully addressed the issue of excessive heterogeneity in the cohort of studies, indicating that it may be inappropriate to combine such dissimilar studies to estimate a common treatment effect. OBJECTIVE: To reanalyze the existing data set for sources of heterogeneity to delineate the population most likely to benefit from HS. DATA SOURCES: We used the previously analyzed cohort of randomized trials from 2 published meta-analyses comparing HS with normal saline (or, in 1 case, with standard of care) in infants hospitalized for bronchiolitis. We also repeated the search strategy used by the most recent Cochrane Review in the Medline database through September 2015. STUDY SELECTION: Eighteen randomized clinical trials of HS in infants with bronchiolitis reporting LOS as an outcome measure were included. DATA EXTRACTION AND SYNTHESIS: The guidelines used for abstracting data included LOS, study year, setting, sample size, type of control, admission/discharge criteria, adjunct medications, treatment frequency, mean day of illness at study enrollment, mean severity of illness scores, and mean age. MAIN OUTCOMES AND MEASURES: Weighted mean difference in LOS and study heterogeneity as measured by the l2 statistic. RESULTS: There were 18 studies included of 2063 infants (63{\%} male), with a mean age of 4.2 months. The mean LOS was 3.6 days. Two main sources of heterogeneity were identified. First, the effect of HS on LOS was entirely sensitive to the removal of one study population, noted to have a widely divergent definition of the primary outcome. Second, there was a baseline imbalance in mean day of illness at presentation between treatment groups. Controllingfor either of these factors resolved the heterogeneity (l2 = reduced from 78{\%} to 45{\%} and 0{\%}, respectively) and produced summary estimates in support of the null hypothesis (that HS does not affect LOS). There was a weighted mean difference in LOS of -0.21 days (95{\%} CI, -0.43 to +0.02) for the sensitivity analysis and +0.02 days (95{\%} CI, -0.14 to +0.17) for studies without unbalanced treatment groups on presentation. CONCLUSIONS AND RELEVANCE: Prior analyses were driven by an outlier population and unbalanced treatment groups in positive trials. Once heterogeneity was accounted for, the data did not support the use of HS to decrease LOS in infants hospitalized with bronchiolitis.",
author = "Brooks, {Corinne G.} and Harrison, {Wade N.} and Shawn Ralston",
year = "2016",
month = "6",
day = "1",
doi = "10.1001/jamapediatrics.2016.0079",
language = "English (US)",
volume = "170",
pages = "577--584",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis

T2 - A reanalysis of 2 meta-analyses

AU - Brooks, Corinne G.

AU - Harrison, Wade N.

AU - Ralston, Shawn

PY - 2016/6/1

Y1 - 2016/6/1

N2 - IMPORTANCE: Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS) in acute viral bronchiolitis have suggested benefit. Neither study fully addressed the issue of excessive heterogeneity in the cohort of studies, indicating that it may be inappropriate to combine such dissimilar studies to estimate a common treatment effect. OBJECTIVE: To reanalyze the existing data set for sources of heterogeneity to delineate the population most likely to benefit from HS. DATA SOURCES: We used the previously analyzed cohort of randomized trials from 2 published meta-analyses comparing HS with normal saline (or, in 1 case, with standard of care) in infants hospitalized for bronchiolitis. We also repeated the search strategy used by the most recent Cochrane Review in the Medline database through September 2015. STUDY SELECTION: Eighteen randomized clinical trials of HS in infants with bronchiolitis reporting LOS as an outcome measure were included. DATA EXTRACTION AND SYNTHESIS: The guidelines used for abstracting data included LOS, study year, setting, sample size, type of control, admission/discharge criteria, adjunct medications, treatment frequency, mean day of illness at study enrollment, mean severity of illness scores, and mean age. MAIN OUTCOMES AND MEASURES: Weighted mean difference in LOS and study heterogeneity as measured by the l2 statistic. RESULTS: There were 18 studies included of 2063 infants (63% male), with a mean age of 4.2 months. The mean LOS was 3.6 days. Two main sources of heterogeneity were identified. First, the effect of HS on LOS was entirely sensitive to the removal of one study population, noted to have a widely divergent definition of the primary outcome. Second, there was a baseline imbalance in mean day of illness at presentation between treatment groups. Controllingfor either of these factors resolved the heterogeneity (l2 = reduced from 78% to 45% and 0%, respectively) and produced summary estimates in support of the null hypothesis (that HS does not affect LOS). There was a weighted mean difference in LOS of -0.21 days (95% CI, -0.43 to +0.02) for the sensitivity analysis and +0.02 days (95% CI, -0.14 to +0.17) for studies without unbalanced treatment groups on presentation. CONCLUSIONS AND RELEVANCE: Prior analyses were driven by an outlier population and unbalanced treatment groups in positive trials. Once heterogeneity was accounted for, the data did not support the use of HS to decrease LOS in infants hospitalized with bronchiolitis.

AB - IMPORTANCE: Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS) in acute viral bronchiolitis have suggested benefit. Neither study fully addressed the issue of excessive heterogeneity in the cohort of studies, indicating that it may be inappropriate to combine such dissimilar studies to estimate a common treatment effect. OBJECTIVE: To reanalyze the existing data set for sources of heterogeneity to delineate the population most likely to benefit from HS. DATA SOURCES: We used the previously analyzed cohort of randomized trials from 2 published meta-analyses comparing HS with normal saline (or, in 1 case, with standard of care) in infants hospitalized for bronchiolitis. We also repeated the search strategy used by the most recent Cochrane Review in the Medline database through September 2015. STUDY SELECTION: Eighteen randomized clinical trials of HS in infants with bronchiolitis reporting LOS as an outcome measure were included. DATA EXTRACTION AND SYNTHESIS: The guidelines used for abstracting data included LOS, study year, setting, sample size, type of control, admission/discharge criteria, adjunct medications, treatment frequency, mean day of illness at study enrollment, mean severity of illness scores, and mean age. MAIN OUTCOMES AND MEASURES: Weighted mean difference in LOS and study heterogeneity as measured by the l2 statistic. RESULTS: There were 18 studies included of 2063 infants (63% male), with a mean age of 4.2 months. The mean LOS was 3.6 days. Two main sources of heterogeneity were identified. First, the effect of HS on LOS was entirely sensitive to the removal of one study population, noted to have a widely divergent definition of the primary outcome. Second, there was a baseline imbalance in mean day of illness at presentation between treatment groups. Controllingfor either of these factors resolved the heterogeneity (l2 = reduced from 78% to 45% and 0%, respectively) and produced summary estimates in support of the null hypothesis (that HS does not affect LOS). There was a weighted mean difference in LOS of -0.21 days (95% CI, -0.43 to +0.02) for the sensitivity analysis and +0.02 days (95% CI, -0.14 to +0.17) for studies without unbalanced treatment groups on presentation. CONCLUSIONS AND RELEVANCE: Prior analyses were driven by an outlier population and unbalanced treatment groups in positive trials. Once heterogeneity was accounted for, the data did not support the use of HS to decrease LOS in infants hospitalized with bronchiolitis.

UR - http://www.scopus.com/inward/record.url?scp=84973610917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973610917&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2016.0079

DO - 10.1001/jamapediatrics.2016.0079

M3 - Article

C2 - 27088767

AN - SCOPUS:84973610917

VL - 170

SP - 577

EP - 584

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 6

ER -